QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene

Zacks09-26 21:03

QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture, PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470753772?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2","is_english":true,"pubTime":"2024-09-26 21:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2470753772","market":"us","top_or_hot":-1,"title":"QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene","media":"Zacks","content":"<div>\n<p>QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture,  PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/qiagen-stock-likely-gain-preanalytixs-130300696.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/qiagen-stock-likely-gain-preanalytixs-130300696.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture,  PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/qiagen-stock-likely-gain-preanalytixs-130300696.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/qiagen-stock-likely-gain-preanalytixs-130300696.html","article_id":"2470753772","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TnZya4zmXcZQTiM85rn8xg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470753772","pubTimestamp":1727355780,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture, PreAnalytiX GmbH, recently launched the PAXgeneUrine Liquid Biopsy Set. PAXgenewill be used for reliable analysis of cell-free DNA  from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing .QIAGEN will commercialize the newly launched set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cfDNA.Following the news, shares of QGEN lost 1.7% to $44.11 yesterday. The company is gaining a high level of synergies from the continuous development within its Sample Technologies product portfolio. We expect the latest launch to motivate market sentiment in favor of QGEN in the coming days.Meanwhile, QGEN currently has a market capitalization of $10.15 billion. In the last reported quarter, it delivered an earnings surprise of 5.77%. The company has a trailing four-quarter average earnings s","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","TMDX":"TransMedics Group Inc.","BK4179":"石油天然气设备与服务","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","QGEN":"快而精医药","BK4504":"桥水持仓","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","KIDS":"Orthopediatrics Corp","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","NGS":"Natural Gas Services Group Inc","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4585":"ETF&股票定投概念","AXGN":"AxoGen Inc.","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BDX":"碧迪医疗","BK4198":"医疗保健用品","BK4588":"碎股","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC"},"translate_title":"QIAGEN股票可能会从PreAnalytiX新推出的PAXgene中受益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1,"TMDX":1,"NGS":1,"KIDS":1,"AXGN":1,"QGEN":0.9},"content_text":"QIAGEN N.V.QGEN and Becton, Dickinson and Company or BD’s BDX joint venture,  PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS).\nQIAGEN will commercialize the newly launched set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cfDNA.\nQGEN’s Likely Stock Trend Following the News\nFollowing the news, shares of QGEN lost 1.7% to $44.11 yesterday. The company is gaining a high level of synergies from the continuous development within its Sample Technologies product portfolio. We expect the latest launch to motivate market sentiment in favor of QGEN in the coming days.\nMeanwhile, QGEN currently has a market capitalization of $10.15 billion. In the last reported quarter, it delivered an earnings surprise of 5.77%.  The company has a trailing four-quarter average earnings surprise of 2.64%.\nAbout PAXgene Urine Liquid Biopsy Set\nPAXgene Urine Liquid Biopsy Set offers a closed configuration set for urine collection and cfDNA stabilization, with a range of options for sample shipment and storage conditions. It is compatible with various downstream analyses, including hotspots, gene panels and genome-wide analyses, each of which can provide important complementary information to blood.\nThis easy-to-use set for urine collection and cfDNA stabilization is also the first to feature a verified, standardized and complete preanalytical workflow to make urine cfDNA more accessible for research analysis. It is developed according to Europe's latest CEN/TS standard for preanalytical handling of urine for isolated cell-free DNA. The CEN/TS designation refers to Technical Specifications developed by the European Committee for Standardization.\nSignificance of the Latest Launch for QGEN\nUrine liquid biopsy has a significant potential to help researchers detect minimal residual disease, monitor treatment response and identify therapeutic targets by complementing the results of blood plasma analysis and providing a more complete understanding. However, no widely established technical solution for urine liquid biopsy is available. With the launch of PAXgene, QIAGEN aims to address the market need for a urine collection, stabilization, transport and storage device that can be integrated into a complete preanalytical workflow for the development of cfDNA-based tests.\nThe newly launched PAXgene will complement other liquid biopsy solutions commercialized by QIAGEN, covering all analytes (circulating cell-free nucleic acids, tumor cells, exosomes) and most molecular detection technologies (NGS, qPCR, digital PCR) to empower researchers and clinicians to fully realize the potential of liquid biopsy across various applications.\nQIGEN’s Recent Development\nQIAGEN recently announced Bode Technology as its exclusive global commercial partner for GEDmatch PRO genealogy database. Its subsidiary, Verogen, inked the deal with Bode. The latest partnership is aimed at accelerating the use of QIAGEN’s NGS products in human identification and forensic investigations.\nImage Source: Zacks Investment Research\nIndustry Prospects Favor QIAGEN\nPer the Maximize Market Research report, the global cfDNA testing market was valued at $9.58 billion in 2023 and is expected to reach $48.03 billion by 2030, growing at a compound rate of 25.90% during the period. Key factors influencing market growth include increasing healthcare expenditure and growing healthcare awareness.\nQGEN Stock’s Price Performance\nIn the past year, shares of QGEN have risen 8.4% against the industry’s 0.4% decline. \nQGEN’s Zacks Rank and Key Picks\nQGEN currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are TransMedics Group TMDX, AxoGen AXGN and OrthoPediatrics KIDS. While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.\nEstimates for TransMedics’ 2024 earnings per share (EPS) have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 160.6% in the past year compared with the industry’s 19.7% growth. TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.\nEstimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 183.6% in the past year compared with the industry’s 19.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.\nEstimates for OrthoPediatrics’ 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 18.7% against the industry’s 19.6% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBecton, Dickinson and Company (BDX) : Free Stock Analysis Report\nQIAGEN N.V. (QGEN) : Free Stock Analysis Report\nAxoGen, Inc. (AXGN) : Free Stock Analysis Report\nOrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report\nTransMedics Group, Inc. (TMDX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470753772"}